Physician profile
Patrick Astourian
NPI 1932294279
$11,942.42
in general payments reported to CMS, 2019-2025
27 companies · $4,014 in 2025
The $4,014 reported for 2025 was more than what 97% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,289 · 2022: $1,333 · 2023: $2,535 · 2024: $2,772 · 2025: $4,014.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,213 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,213.45 |
| Education | $107.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,546.69 | 2021-2025 | |
| Amgen INC. | $1,894.63 | 2021-2025 | Enbrel, Otezla, Otezla |
| Janssen Biotech, INC. | $1,870.74 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Mallinckrodt Hospital Products INC. | $715.08 | 2023-2025 | Acthar |
| Ucb, INC. | $574.75 | 2022-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $512.82 | 2021-2025 | |
| Glaxosmithkline, LLC. | $439.46 | 2021-2025 | Benlysta, Nucala |
| Aurinia Pharma U.S., INC. | $415.77 | 2021-2025 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $403.97 | 2021-2025 | Ofev |
| Astrazeneca Pharmaceuticals Lp | $386.23 | 2021-2025 | Saphnelo |
| Lilly USA, LLC | $374.57 | 2021-2025 | Olumiant, Taltz, Zepbound |
| Horizon Therapeutics Plc | $332.84 | 2021-2023 | Krystexxa |
| Pfizer INC. | $286.53 | 2021-2025 | |
| Bioventus LLC | $239.71 | 2021-2025 | Durolane, Xcell |
| Ani Pharmaceuticals, INC. | $212.89 | 2025 | Purified Cortrophin Gel, Sovuna |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $169.81 | 2021-2025 | |
| Heartflow, INC. | $149.90 | 2025 | |
| Janssen Scientific Affairs, LLC | $119.80 | 2021 | |
| Abbott Laboratories | $64.15 | 2022 | |
| Scilex Pharmaceuticals INC. | $61.01 | 2024 | |
| Genzyme Corporation | $56.29 | 2024 | |
| Kyowa Kirin, INC. | $25.73 | 2025 | |
| Sobi, INC | $25.14 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $19.97 | 2021 | |
| Almatica Pharma LLC | $18.73 | 2024 | Teriparatide |
| Actelion Pharmaceuticals US, INC. | $13.13 | 2025 | Opsynvi, Uptravi |
| Alexion Pharmaceuticals, INC. | $12.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Astourian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.